OFS plus AI or SERM vs. SERM alone in premenopausal women with hormone receptor-positive breast cancer: a prospective cohort study using the real-world database

Background Ovarian function suppression (OFS) plus other endocrine treatment was recommended to hormone receptor (HR)-positive breast cancer by some guidelines recently. We performed this study to validate the survival benefits of OFS plus aromatase inhibitors (AI) or selective estrogen receptor mod...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Breast cancer (Tokyo, Japan) Japan), 2019-05, Vol.26 (3), p.339-348
Hauptverfasser:	Hu, Kejia, He, Ping, Peng, Qian, Zhong, Xiaorong, Deng, Ling, Xie, Yuxin, Li, Jiayuan, Xu, Hongping, Lu, Donghao, Zheng, Hong
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Analysis Antineoplastic Agents, Hormonal - pharmacology Antineoplastic Agents, Hormonal - therapeutic use Antineoplastic Combined Chemotherapy Protocols - pharmacology Antineoplastic Combined Chemotherapy Protocols - therapeutic use Aromatase Inhibitors - pharmacology Aromatase Inhibitors - therapeutic use Breast Neoplasms - metabolism Breast Neoplasms - mortality Breast Neoplasms - pathology Breast Neoplasms - therapy Cancer Cancer Research Combined Modality Therapy Disease-Free Survival Estrogen Female Goserelin - pharmacology Goserelin - therapeutic use Hormones Humans Medicin och hälsovetenskap Medicine Medicine & Public Health Menopause Middle Aged Oncology Oncology, Experimental Original Article Ovariectomy Ovary - drug effects Ovary - physiopathology Ovary - surgery Premenopause Prospective Studies Receptors, Estrogen - metabolism Receptors, Progesterone - metabolism Selective Estrogen Receptor Modulators - pharmacology Selective Estrogen Receptor Modulators - therapeutic use Surgery Surgical Oncology Survival Rate Women
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!